Changfeng Pharmaceuticals Stock Surges Strongly; IND Application for Self-Developed Pulmonary Arterial Hypertension New Drug Accepted

NightAirdropper · 2026-03-16T18:24:08+00:00

Changfeng Pharmaceutical's stock price surged significantly on March 16, with gains exceeding 40% at their peak. The main driver was the National Medical Products Administration's acceptance of a new drug clinical trial application for ICF001, the company's inhalation powder aerosol candidate drug. This medication targets pulmonary arterial hypertension and other diseases, offering patients new treatment options and marking an important breakthrough in the company's research and development efforts.

NightAirdropper

2026-03-16 18:24:08

Abstract generation in progress

On March 16, Changfeng Pharmaceutical performed well in the capital market, with its stock price showing a volatile upward trend, once rising more than 40% during the trading session. The highest price reached HKD 32.88 per share. As of 10:54 a.m., the company’s stock price was HKD 30.76 per share, up 33.74%, with a daily trading volume of approximately HKD 130.6 million, and its total market value increased to about HKD 12.66 billion.

The significant rise in stock price is driven by important progress in Changfeng Pharmaceutical’s drug research and development. On March 13, the company announced that its self-developed inhaled powder aerosol candidate drug ICF001’s new drug clinical trial (IND) application has been officially accepted by the National Medical Products Administration (NMPA).

ICF001 is an innovative long-acting inhaled powder aerosol developed based on Changfeng Pharmaceutical’s prodrug technology platform. The drug mainly targets pulmonary arterial hypertension and related severe lung diseases, offering new treatment options for patients with these conditions. The acceptance of the clinical trial application marks a key step forward in the development of ICF001. If subsequent clinical trials are successful and the drug is approved for market launch, it will have a positive impact on the company’s growth.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes